Skip to main content

Table 3 Haemophagocytic lymphohistiocytosis features and immune-related adverse events reported in patients treated with immune checkpoint inhibitors

From: Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports

Clinical features of HLH Patients No. (%) a
(n = 38)
Pyrexia 2 (5)
Pulmonary involvement
 Cough 1 (3)
Neurological involvement
 Encephalopathy 1 (3)
 Headache 1 (3)
Psychiatric changes
 Delirium 1 (3)
Cutaneous involvement
 Generalised erythema 1 (3)
 Drug eruption 1 (3)
Gastrointestinal involvement
 Enterocolitis 1 (3)
 Diarrhoea 2 (5)
Renal involvement
 Renal failure 1 (3)
 Renal tubular necrosis 1 (3)
Haematological and coagulation features of HLH
 Anaemia 1 (3)
 Thrombocytopenia 2 (5)
 Leukopenia/ White blood cell count decreased 2 (5)
 Neutrophil count decreased 1 (3)
 Disseminated intravascular coagulation 3 (8)
 International normalised ratio abnormal 1 (3)
 Pancytopenia/ Bone marrow failure 2 (5)
Concurrent irAEs
 Autoimmune hepatitis 2 (5)
 Interstitial lung disease 2 (5)
 Myositis 1 (3)
 Thyroiditis 1 (3)
 Cardiacb 1 (3)
  1. Abbreviations: HLH haemophagocytic lymphohistiocytosis, irAEs immune-related adverse events
  2. a Some patients reported more than one adverse drug reaction besides HLH
  3. b Atrial fibrillation and left ventricular failure